Shawn Krairit

Under the supervision of Professor Patric Turowski, I conducted in-depth research on the blood-brain barrier and the biological effects of phospholipids, such as lysophosphatidic acid and lysophosphatidylcholine. I was actively involved in experiments using primary pig brain endothelial cells to model and assess the integrity of the blood-brain barrier. Using advanced techniques like transendothelial electrical resistance and flux assays, I measured barrier permeability and applied statistical analysis, including variance analysis and t-tests, to evaluate the impact of various phospholipid isoforms. My work led to the development of a successful in vitro blood-brain barrier model, providing critical insights into how these phospholipids influence barrier integrity. This research contributed to a deeper understanding of neuroinflammatory diseases and laid the groundwork for potential therapeutic approaches.

In this role, I was responsible for reviewing and critiquing clinical trial data, identifying errors and inconsistencies to improve overall data integrity. I applied statistical techniques to analyse datasets, uncover meaningful trends, and support clinical outcomes. Collaborating closely with senior researchers, I helped prepare comprehensive reports, summarising key findings and offering actionable recommendations. My efforts led to the identification and correction of critical data issues, significantly improving the reliability of trial results. Additionally, I played a key role in the successful completion of a trial phase by providing precise data validation and analysis, while streamlining the data analysis process through the introduction of efficient review protocols, which reduced error rates and enhanced accuracy.

In this role, I managed the preparation and organisation of crucial trial documentation, ensuring all materials met clinical standards and regulatory requirements. I proactively identified gaps and inconsistencies in documentation and processes, offering targeted recommendations to enhance accuracy and efficiency. Additionally, I facilitated seamless communication across trial teams, ensuring smooth coordination and consistent information sharing. By improving the accuracy of trial documentation and addressing errors early on, I contributed to more streamlined clinical trial operations. My efforts in refining communication protocols enabled more effective collaboration between team members and stakeholders, while my focus on adherence to industry standards helped mitigate compliance risks.

I conducted in-depth cancer research, focusing on immunotherapy-treated rat models of prostate cancer, where I closely monitored tumour progression and necrosis. I employed advanced immunostaining techniques to accurately identify and quantify tumour and necrotic tissues within prostate samples. My role also involved utilising cryo-slicing methods to meticulously prepare tissue samples for further analysis. I maintained precise records of experimental results, ensuring data accuracy throughout the study. By interpreting and presenting my findings to the research team, I contributed valuable insights into the effects of immunotherapy on cancer. This research led to the identification of significant differences between treated and control groups, advancing the understanding of immunotherapy's efficacy. Additionally, I honed my expertise in staining techniques and cryo-slicing, enhancing tissue analysis accuracy and supporting ongoing prostate cancer research.